So far no definite therapeutic effectiveness has been demonstrated for any of conventional treatments for idiopathic aplastic anemia and patients with aplastic anemia have been rarely cured.
Corticosteroids have been considered to be not curative but supportive in the treatment of aplastic anemia. In our country, Umehara et al. (1960) reported therapeutic effectiveness of a long-term administra tion of corticosteroids in a relatively small dosis in the treatment of aplastic anemia. Since then, many reports have documented the effects of corticosteroids in prolonging the survival of the patients. In our clinic, the patients with aplastic anemia have been treated since 1960 with a long-term administration of corticoster oids in large dosis, and remarkable hematological as well as clinical improvement has been obtained. However, hematological remission or cure following corticosteroid therapy usually appeared more than 6 months after initiation of the therapy.
So, the risk associated with a long-term corticosteroid therapy must be seriously taken into account, and prolonged treatment should be performed with the greatest care. Therapeutic effects of long-term corticosteroid therapy and prognosis of patients are greatly influenced by the complication in the course of treatment. 54%. In patients with hyperplastic form, the results were poor. The relation ship between daily dosage of prednisolone and therapeutic effect is shown in Table  5 . In the patients who were administered daily dosis of 30 mg prednisolone, the range of total dosis of the drugs was 1316 to 17685.5 mg with a median of 4984 mg, while in the group of patients who received 20 mg prednisolone daily, the range was 567 to 15570 mg with a median of 6810.5 mg. The duration of prednisolone administration ranged from 70 to 873 days (median 203 days) in the former group and 27 to 1109 days (median 417 days) in the later. In the group which received 20 mg/day, 15 out of 33 patients were cured, 3 had remissions, 4 were improved, thus the response rate was 67%, and cure-remission rate was 55%. In the group of 30 mg/day, 5 of 22 patients were cured, 2 had remissions, 6 were improved, thus the response rate was 59%, and cure-remission rate was 32%. The responses in the group treated with 30 mg/day were poor as compared with those in 20 mg/day group. The difference might be due to the high incidence of severe compli cations in this group. In 30 mg/day group, 73% of the patients died, whereas the mortality rate in the 20 mg/day group was 36%. The relationship between hematological findings and the response to the therapy was shown in Tables 6 and 7 . There were no significant differences in peripheral blood findings between responders and non-responders. All patients with bone marrow plasmacytes more than 7% showed poor results. The relationship between erythropoietic activity measured by ferrokinetic techniques and the response to the therapy was shown in Table 8 . No significant differences were seen in the values of PITR and % RCUt between responders and non-responders.
MATERIALS AND METHODS
Hematological findings during the treatment. Hematological changes observed in the patients whose bone marrow had recovered to remission or cure states from initial aplastic or hypoplastic states following the corticosteroid therapy were shown in Tables 9 and 10 . When the treatment was effective, increases in erythroblasts of the bone marrow and in peripheral blood reticulocytes occurred at first usually within 1 to 3 months after the initiation of the treatment (response period). However, in this period bone marrow cellularity was still low and no definite improvement of peripheral blood finding was observed. This kind of initial response was also observed in the patients who were not cured. Namely, the response did not always lead to normalization of blood cell elements. In cured cases further improvement followed the initial response. An increase of nucleated Side effect. Cushingnoid was observed in almost all patients. The most important complications were steroid diabetes, infection including hepatitis, osteoporosis and adrenal failure. Steroid diabetes was observed in 45% of 55 patients; or in 55% of the patients treated with a daily dosis of 20 mg predniso lone and in 32% with a daily dosis of 30 mg prednisolone. The difference might be due to the different length of the treatment courses. Steroid diabetes was well controlled with insulin. Infection was the most serious life-threatening complication and observed in 33% of the patients. With regard to liver toxicity following corticosteroid therapy, elevated GOT and GPT were observed in 29% of the patients. Osteoporosis was observed in 18% of the patients treated with a daily dosis of 20 mg prednisolone. Adrenal failure was seen in 3 of 55 patients. These complications subsided gradually after the discontinuation of the therapy (Table 11) . the methods of administration of the drugs, severity of disease treated and criteria of evaluation of therapeutic effect. In the reports of aplasic anemia from foreign countries, many patients considered to be of symptomatic and mild type are included, while almost all patients presented here are those with idiopathic and severe aplastic anemia. It is evident that therapeutic effect and prognosis of the disease have a close relation ship with severity of disease.
It was reported that the patients who showed markedly decreased erythropoiesis hardly responded to therapy (Miyazaki et al. 1973 ). In our data the same tendency was seen, but cure was also obtained even in patients with markedly decreased erythropoiesis. Therapeutic effect was different between acute and chronic aplastic anemia.
Concerning therapeutic effect of corticosteroid, only curative effect was given great weight, because spontaneous cure hardly occurs. Clinical improvement and remission which are sometimes observed spontaneously or by conventional treatment are often transient and the patients are always exposed to the risk of relapse.
If cure was really obtained, relapse rarely occurred after the cessation of the treatment.
The mechanism of glucocorticoid action was not so definitely known. However, it had been shown by many hematologists in Europe and America that glucocorticoids had no stimulating effect on hemopoiesis or facilitating effect on hematological recovery in aplastic anemia. The use of glucocorticoid in the therapy of aplastic anemia has been thought to be beneficial only in the initial phase when severe bleeding can be improved by the coagulant action of the drug. However, in our country, Umehara et al. (1960) and Yamagata et al. (1962) reported stimulating effect of glucocorticoid on hemopoiesis. Ito (1966) were presented. In our present investigation a mortality rate of 36% was obtained. It is evident that corticosteroid therapy, especially prolonged use of the drug, improved prognosis of the patients with aplastic anemia. However, cure was hitherto hardly attained. In the present study, 20 of 55 patients with aplastic anemia had cured; particularly, the patients treated with a daily dosis of 20 mg prednisolone revealed a high ratio of cure (45%). All these cured cases except one have been maintaining normal hematological findings and healthy conditions during the period of 6 to 149 months after the cessation of the treatment. There is no unanimous opinion as to the hematological effect of corticosteroid Hasegawa et al. (1960) stated that when corticosteroids were administered for a long period, bleeding was ameliorated, the bone marrow could consequently rest and its spontaneous recovery might be facilitated. But constant interval before the therapeutic response and regular changes in peripheral and bone marrow picture observed in all effective cases makes such opinion improbable. Umehara et al (1968) pointed out anti-inflammatory action of corticosteroid as an important factor for improvement of the disease.
Based on the observation of hematological changes in the patients of remis sion or cure, we conclude that corticosteroid has a direct effect on hemopoiesis as well as anti-inflammatory action on the changes of bone marrow matrix.
